Patrick T Wilson1, Frank Baiden2, Joshua C Brooks3, Marilyn C Morris4, Katie Giessler5, Damien Punguyire6, Gavin Apio7, Akua Agyeman-Ampromfi8, Sara Lopez-Pintado9, Justice Sylverken10, Kwadwo Nyarko-Jectey11, Harry Tagbor12, Rachel T Moresky13. 1. Department of Pediatrics, Columbia University, New York, NY, USA; Department of Population and Family Health, Columbia University, New York, NY, USA. Electronic address: ptw2107@cumc.columbia.edu. 2. Epidemiology Unit, Ensign College of Public Health, Kpong, Ghana. 3. School of Medicine, University of Queensland-Ochsner, Brisbane, QLD, Australia. 4. Department of Pediatrics, Columbia University, New York, NY, USA. 5. Global Health Sciences, University of California San Francisco, San Francisco, CA, USA. 6. Municipal Health Directorate, Techiman, Ghana. 7. Kintampo Municipal Hospital, Kintampo, Ghana. 8. Centre for Global Health Research, Jauben, Ghana. 9. Department of Biostatistics, Columbia University, New York, NY, USA. 10. Department of Pediatrics, Komfo Anokye Teaching Hospital, Kumasi, Ghana. 11. Mampong Municipal Hospital, Mampong, Ghana. 12. School of Medicine, University of Health and Allied Sciences, Ho, Ghana. 13. sidHARTe Program, Department of Population and Family Health, Mailman School of Public Health, Columbia University, New York, NY, USA; Department of Emergency Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Abstract
BACKGROUND: In low-income and middle-income countries, invasive mechanical ventilation is often not available for children at risk of death from respiratory failure. We aimed to determine if continuous positive airway pressure (CPAP), a form of non-invasive ventilation, decreases all-cause mortality in children with undifferentiated respiratory distress in Ghana. METHODS: This open-label, cluster, crossover trial was done in two Ghanaian non-tertiary hospitals where invasive mechanical ventilation is not routinely available. Eligible participants were children aged from 1 month to 5 years with a respiratory rate of more than 50 breaths per min in children 1-12 months old, or more than 40 breaths per min in children older than 12 months, and use of accessory muscles or nasal flaring. CPAP machines were allocated to one hospital during each study block, while the other hospital served as the control site. The initial intervention site was randomly chosen using a coin toss. 5 cm of water pressure was delivered via CPAP nasal prongs. The primary outcome measure was all-cause mortality rate at 2 weeks after enrolment in patients for whom data were available after 2 weeks. We also did post-hoc regression analysis and subgroup analysis of children by malaria status, oxygen saturation, and age. This study is registered with ClinicalTrials.gov, number NCT01839474. FINDINGS:Between Jan 20, 2014, and Dec 5, 2015, 2200 children were enrolled: 1025 at the intervention site and 1175 at the control site. Final analysis included 1021 patients in the CPAP group and 1160 patients in the control group. 2 weeks after enrolment, 26 (3%) of 1021 patients in the CPAP group, and 44 (4%) of 1160 patients in the control group, had died (relative risk [RR] of mortality 0·67, 95% CI 0·42-1·08; p=0·11). In children younger than 1 year, all-cause mortality was ten (3%) of 374 patients in the CPAP group, and 24 (7%) of 359 patients in the control group (RR 0·40, 0·19-0·82; p=0·01). After adjustment for study site, time, and clinically important variables, the odds ratio for 2-week mortality in the CPAP group versus the control group was 0·4 in children aged up to 6 months, 0·5 for children aged 12 months, 0·7 for children aged 24 months, and 1·0 for those aged 36 months. 28 patients (3%) in the CPAP group and 24 patients (2%) in the control group had CPAP-related adverse events, such as vomiting, aspiration, and nasal, skin, or eye trauma. No serious adverse events were observed. INTERPRETATION: In the unadjusted analysis the use of CPAP did not decrease all-cause 2-week mortality in children 1 month to 5 years of age with undifferentiated respiratory distress. After adjustment for study site, time, and clinically important variables, 2-week mortality in the CPAP group versus the control group was significantly decreased in children 1 year of age and younger. CPAP is safe and improves respiratory rate in a non-tertiary setting in a lower-middle-income country. FUNDING: General Electric Foundation.
RCT Entities:
BACKGROUND: In low-income and middle-income countries, invasive mechanical ventilation is often not available for children at risk of death from respiratory failure. We aimed to determine if continuous positive airway pressure (CPAP), a form of non-invasive ventilation, decreases all-cause mortality in children with undifferentiated respiratory distress in Ghana. METHODS: This open-label, cluster, crossover trial was done in two Ghanaian non-tertiary hospitals where invasive mechanical ventilation is not routinely available. Eligible participants were children aged from 1 month to 5 years with a respiratory rate of more than 50 breaths per min in children 1-12 months old, or more than 40 breaths per min in children older than 12 months, and use of accessory muscles or nasal flaring. CPAP machines were allocated to one hospital during each study block, while the other hospital served as the control site. The initial intervention site was randomly chosen using a coin toss. 5 cm of water pressure was delivered via CPAP nasal prongs. The primary outcome measure was all-cause mortality rate at 2 weeks after enrolment in patients for whom data were available after 2 weeks. We also did post-hoc regression analysis and subgroup analysis of children by malaria status, oxygen saturation, and age. This study is registered with ClinicalTrials.gov, number NCT01839474. FINDINGS: Between Jan 20, 2014, and Dec 5, 2015, 2200 children were enrolled: 1025 at the intervention site and 1175 at the control site. Final analysis included 1021 patients in the CPAP group and 1160 patients in the control group. 2 weeks after enrolment, 26 (3%) of 1021 patients in the CPAP group, and 44 (4%) of 1160 patients in the control group, had died (relative risk [RR] of mortality 0·67, 95% CI 0·42-1·08; p=0·11). In children younger than 1 year, all-cause mortality was ten (3%) of 374 patients in the CPAP group, and 24 (7%) of 359 patients in the control group (RR 0·40, 0·19-0·82; p=0·01). After adjustment for study site, time, and clinically important variables, the odds ratio for 2-week mortality in the CPAP group versus the control group was 0·4 in children aged up to 6 months, 0·5 for children aged 12 months, 0·7 for children aged 24 months, and 1·0 for those aged 36 months. 28 patients (3%) in the CPAP group and 24 patients (2%) in the control group had CPAP-related adverse events, such as vomiting, aspiration, and nasal, skin, or eye trauma. No serious adverse events were observed. INTERPRETATION: In the unadjusted analysis the use of CPAP did not decrease all-cause 2-week mortality in children 1 month to 5 years of age with undifferentiated respiratory distress. After adjustment for study site, time, and clinically important variables, 2-week mortality in the CPAP group versus the control group was significantly decreased in children 1 year of age and younger. CPAP is safe and improves respiratory rate in a non-tertiary setting in a lower-middle-income country. FUNDING: General Electric Foundation.
Authors: Eric D McCollum; Andrew G Smith; Michelle Eckerle; Tisungane Mvalo; Katherine L O'Brien; Abdullah H Baqui Journal: Lancet Respir Med Date: 2017-11-10 Impact factor: 30.700
Authors: Sarah Myers; Precious Dinga; Margot Anderson; Charles Schubert; Rachel Mlotha; Ajib Phiri; Tim Colbourn; Eric Douglass McCollum; Charles Mwansambo; Peter Kazembe; Hans-Joerg Lang Journal: BMJ Open Respir Res Date: 2019-03-08
Authors: Eric D McCollum; Tisungane Mvalo; Michelle Eckerle; Andrew G Smith; Davie Kondowe; Don Makonokaya; Dhananjay Vaidya; Veena Billioux; Alfred Chalira; Norman Lufesi; Innocent Mofolo; Mina Hosseinipour Journal: Lancet Respir Med Date: 2019-09-24 Impact factor: 30.700
Authors: Saraswati Kache; Mohammod Jobayer Chisti; Felicity Gumbo; Ezekiel Mupere; Xia Zhi; Karthi Nallasamy; Satoshi Nakagawa; Jan Hau Lee; Matteo Di Nardo; Pedro de la Oliva; Chhavi Katyal; Kanwaljeet J S Anand; Daniela Carla de Souza; Vanessa Soares Lanziotti; Joseph Carcillo Journal: Pediatr Res Date: 2020-07-07 Impact factor: 3.756
Authors: Ashley Bjorklund; Tina Slusher; Louise Tina Day; Mariya Mukhtar Yola; Clark Sleeth; Andrew Kiragu; Arianna Shirk; Kristina Krohn; Robert Opoka Journal: Front Pediatr Date: 2022-01-31 Impact factor: 3.418